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Summary
Objective: To determine whether opportunistic oral infections associated to HIV infection (OOI-HIV) are found in 
HIV+/AIDS patients with immune reconstitution related to highly active antiretroviral therapy (HAART). 
Methods. From among 1100 HIV+/AIDS patients (Service of Internal Medicine, Carlos Haya Hospital, Malaga, 
Spain) subjected to review of the oral cavity between January 1996 and May 2007, we identified those examined in 
1996 and which were again examined between 1997 and 2007, and were moreover receiving HAART. The following 
data were collected: age, gender, form of contagion, antiretroviral therapy at the time of review, number of CD4+ 
lymphocytes/ml, and viral load (from 1997 onwards). We identified those subjects with an increase in CD4+ lympho-
cytes/ml associated to HAART, and classified them as subjects with quantitative evidence of immune reconstitution 
(QEIR). Among these individuals with QEIR we moreover identified those with undetectable viral loads (QEIR+VL), 
and differentiated those patients with an increase in CD4+ lymphocytes >500/ml (QEIRm+VL). In each group we 
determined the prevalence of OOI-HIV, following the diagnostic recommendations of the EC-Clearinghouse (CDC-
Atlanta, USA - WHO). In addition, we analyzed the prevalence of OOI-HIV in the different groups in relation to 
the duration of HAART.
Results. A total of 86 subjects were included (44 females and 42 males; 19 heterosexuals, 34 male homosexuals, and 33 
intravenous drug abusers). Forty-two patients showed QEIR: 21 belonged to the QEIR+VL group, and 17 conformed 
the QEIRm+VL group. The prevalence of OOI-HIV per group was as follows: QEIR = 54.8%; QEIR+VL = 33%; 
QEIRm+VL = 35%. The most prevalent lesion in all groups was erythematous candidiasis. OOI-HIV increased with 
the duration of HAART (p = 0.008), and were seen to be dependent upon late appearance of the mycotic lesions 
(after 24 months under HAART). 
Conclusions: It is suggested that opportunistic oral infections associated to HIV infection form part of the clinical 
picture of immune reconstitution inflammatory syndrome, though such infections are of late onset.
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Introduction
Human immunodeficiency virus (HIV) infection is cha-
racterized by a gradual reduction in the counts of CD4+ 
lymphocytes, among other cells, to the point of complete 
depletion (1-3). This reduction in turn leads to opportunis-
tic infections and specific neoplastic processes. The intro-
duction of highly active antiretroviral therapy (HAART) 
in the mid-nineties led to a decrease in the morbidity and 
mortality associated to HIV infection. However, it was 
seen that some patients under HAART who showed impro-
vements in their immune system (immune reconstitution) 
paradoxically also developed clinical outbreaks of infec-
tious diseases (4,5). This phenomenon was referred to as 
“immune reconstitution inflammatory syndrome” (IRIS), 
or immune reconstitution syndrome (IRS), immune resti-
tution syndrome, immune reconstruction disease, immune 
restoration disease, among other terms. Thus, IRIS can be 
defined as the situation in which pre-existing subclinical 
or moderately symptomatic infections or inflammatory 
conditions paradoxically undergo worsening with a subs-
tantial increase in inflammation during the initial months 
of  host immune reconstitution as a result of  HAART 
(6). Although the pathogenesis of IRIS is still far from 
clear, the proposed mechanisms comprise a normal but 
vigorous pathogen-specific immune response; an immuno-
pathogenic response; or a hyperinflammatory response to 
some pathogen (either intact or involving particles of the 
pathogen, or its residual antigens) already present at the 
time of rapid immune reconstitution (5,7) - thus suggesting 
restoration of host antigen-specific immunity.
Among the opportunistic infections strongly associated to 
HIV infection, mention must be made of the opportunistic 
oral infections (OOI-HIV). Certain OOI-HIV, specifically 
oral candidiasis (OC) and hairy leukoplakia (HL), have been 
attributed strong diagnostic and prognostic value (8,9). Mo-
reover, they recently have been proposed as clinical markers 
of antiretroviral therapy failure (10). Despite the presence 
of elements warranting the inclusion of oral lesions as part 
of IRIS, and the presence of concrete pathogens prior to 
immune reconstitution (1), the behavior of opportunistic 
oral infections in subjects with immune reconstitution has 
not been investigated to date. The principal objective of the 
present study is to determine whether opportunistic oral 
infections associated to HIV infection are able to form part 
of the clinical picture of immune reconstitution in HIV+/
AIDS subjects receiving HAART. 
Material and Methods
A database comprising 1100 HIV+/AIDS patients from 
the Service of Internal Medicine (Carlos Haya Hospital, 
Malaga, Spain) was used in the present study. All patients 
were subjected to exhaustive review of the oral cavity by 
the same explorer, during the period between January 1996 
and May 2007. The following data were obtained from the 
medical records: age at the time of review, gender, form 
of contagion, antiretroviral therapy at the time of review, 
number of CD4+ lymphocytes/ml, and the number of 
copies of HIV-1 RNA/ml of peripheral blood (viral load, 
VL). This latter parameter was determined on a routine 
basis starting in 1997; as a result, the reviews before this 
period do not contemplate this information. Starting in 
1997, this center specialized in HIV infection adopted as 
first-choice antiretroviral treatment the combination of 
two nucleoside analog reverse transcriptase inhibitors 
(NRTIs) plus an HIV-1 protease inhibitor (PI) - confor-
ming highly active antiretroviral therapy (HAART). 
We thus selected those patients subjected to oral review 
before HAART (pre-HAART era) and which posteriorly 
again underwent oral review subjected to a minimum of 6 
months of HAART (with full adherence to therapy).
The selected subjects were classified according to their 
CD4+ lymphocyte counts as follows: mild immune de-
pression (CD4+ lymphocyte count > 500/ml), moderate 
immune depression (CD4+ lymphocytes > 200 - <500/
ml), and severe immune depression (CD4+ lymphocytes 
< 200/ml). According to viral load, the selected subjects 
were grouped as follows: undetectable VL; VL <10,000 
copies/ml, and VL >10,000 copies/ml.
For investigational purposes only, the subjects were 
distributed into a series of study groups based on IRIS 
risk defined as CD4+ lymphocytes <50/ml at the start of 
HAART, and high viral loads at the start of HAART - im-
mune reconstitution in turn being defined as the increase 
in CD4+ lymphocytes associated with the introduction 
of HAART:
- Subjects with quantitative evidence of immune reconsti-
tution (QEIR). These were patients with a rise in CD4+ 
lymphocyte counts associated to HAART, i.e., those who 
in the pre-HAART era presented CD4+ lymphocyte 
counts of <200/ml, followed by a rise in the HAART era 
to >200 - <500/ml, or >500/ml. Alternatively, these were 
patients with CD4+ lymphocyte counts of >200 - <500/ml 
in the pre-HAART era, followed by a rise in the HAART 
era to >500 CD4+ lymphocytes/ml.
- Subjects with quantitative evidence of immune reconsti-
tution and with viremia control (QEIR+VL). These were 
patients with a rise in CD4+ lymphocyte counts associated 
to HAART, i.e., those who in the pre-HAART era presen-
ted CD4+ lymphocyte counts of <200/ml, followed by a 
rise in the HAART era to >200 - <500/ml, or >500/ml. 
Alternatively, these were patients with CD4+ lymphocyte 
counts of >200 - <500/ml in the pre-HAART era, followed 
by a rise in the HAART era to >500 CD4+ lymphocytes/
ml. In addition to these lymphocyte counts, these patients 
showed an undetectable viral load.
- Subjects with quantitative evidence of maximum immune 
reconstitution and with viremia control (QEIRm+VL). 
These were patients showing an immune response, rea-
ching CD4+ lymphocyte counts of >500/ml, with unde-
tectable viral loads.
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In each of the different study groups we determined the 
prevalence of  oral lesions associated to HIV infection 
(OL-HIV). The diagnosis of the different OL-HIV was 
based on the recommendations of  the CDC-Atlanta 
(USA - WHO) applicable in each period. The diagnosis 
of oral candidiasis was based on the clinical evidence and 
on standardized microbiological methods (culture as well 
as morphology). In addition, with the purpose of deter-
mining whether the duration of HAART influences the 
type and number of oral lesions, an analysis was made of 
the presence of oral lesions in the different study groups 
according to the duration of HAART. 
The statistical methodology was based on the chi-square 
test (EPI-INFO, CDC-Atlanta, USA) for the bivariate 
analysis (p<0.05, 95%CI), while linear logistic regression 
was used (time determination of the curve)(SPSS® ver-
sion 13.0 statistical package)(p<0.05) for analyzing the 
behavior over time of OOI-HIV in relation to the duration 
of HAART.
Results
- Demographic data
Eighty-six long-time survivors (44 females and 42 males) 
were seen to meet the study inclusion criteria. As regards 
the form of contagion, 19 were heterosexuals, 34 were male 
homosexuals, and 33 were intravenous drug abusers.
At the start of the study period (pre-HAART era), the 
mean age of the 86 patients was 34.4 ± 8.8 years, with 
a range of  21-64 years. In this period, and according 
to immune status, the subjects were grouped as follows: 
22 had CD4+ lymphocyte counts of  >500/ml; 22 had 
counts of >200 - <500/ml, and 42 (48.8%) showed severe 
immune deficiency (CD4+ lymphocyte counts of <200/
ml). The copies of HIV-1 RNA/ml (viral load, VL) were 
not used to monitor virological status on a routine basis 
until 1997; as a result, these values are not reported for 
the pre-HAART era.
Regarding immune status in the HAART era, the pa-
tients were distributed as follows: 30 (34.8%) presented 
mild immune deficiency, 28 (32.5%) moderate immune 
deficiency, and 28 (32.5%) severe immune deficiency. As 
to virological status, the individuals corresponding to the 
HAART era showed undetectable viral loads in 39 cases 
(45.3%), while 25 (29%) presented viral loads of <10,000 
copies rna-HIV-1/ml, and 22 subjects presented viral loads 
of >10,000 copies of rna-HIV-1/ml.
- Response to highly active antiretroviral therapy
A decrease was seen in the number of subjects with severe 
immune deficiency in the HAART era, compared with the 
situation in the pre-HAART era (from 48.8% to 32.5%; p = 
0.02). Regarding the patients with QEIR, a total of 42 sub-
jects (representing 48% of the total patient series) increased 
their CD4+ lymphocyte counts while receiving HAART.
In relation to the viral loads, the absence of this parameter 
in the pre-HAART era does not allow us to establish com-
parisons. However, the data corresponding to the HAART 
era show a 45.3% success rate with antiretroviral therapy, 
defined by the presence of undetectable viral loads.
On relating the two paraclinical markers (CD4+ lym-
phocyte count and VL) in each of  the subjects in the 
HAART era, 21 (24.4%) of the 86 patients with increases 
in their CD4+ lymphocyte counts moreover also showed 
undetectable viral loads (QEIR+VL group). Since it has 
been suggested that immune reconstitution syndrome is 
more likely in subjects with greater reconstitution of the 
immune system, we identified those patients who in the 
pre-HAART era had CD4+ lymphocyte counts of <200/
ml and who under HAART reached counts of >500/ml 
together with viremia control as reflected by the presence 
of undetectable viral loads (QEIRm+VL group). A total 
of 17 of the 86 patients in the present analysis met these 
criteria. The distribution of the different study groups and 
subgroups is reported in Table 1.
Prevalence of opportunistic oral infections related to HIV 
- Pre-HAART era
The prevalence of OOI-HIV in this pre-HAART era was 
found to be 66.3%, since 57 subjects presented OOI-HIV 
of some kind. The most common lesion was erythematous 
candidiasis, with 27 cases (31.4%), followed by angular 
cheilitis with 20 cases (23.3%), hairy leukoplakia (HL) 
with 18 cases (20.9%), and pseudomembranous candidia-
sis with a prevalence of 12.8%. Six cases of hyperplastic 
candidiasis were diagnosed (7%), as well as 7 cases of lip 
herpes (8.1%) and 4 cases of Kaposi sarcoma (4.7%).
- HAART era
The prevalence of opportunistic infections in the HAART 
era was 46.5% (40 cases). The most frequent lesion was 
erythematous candidiasis with 25 cases (29.1%), followed 
by hairy leukoplakia with 20 cases (prevalence 23.3%). 
Eight patients presented angular cheilitis (9.4%), and 4 
were diagnosed with pseudomembranous candidiasis 
(4.7%). One case of lip herpes was registered (1.2%). This 
group of long-term survivors receiving HAART showed 
no cases of hyperplastic candidiasis or Kaposi sarcoma. 
Thus, a decrease was seen in morbidity attributable to 
opportunistic oral infections in the HAART era - though 
statistically significant differences (p<0.05) were only re-
corded in relation to angular cheilitis and lip herpes. The 
total oral lesions and their respective prevalences in both 
eras are reported in Table 2. 
Opportunistic oral infections in the study groups
In concordance with the principal objective of the stu-
dy, we identified those subjects with opportunistic oral 
infections in the different study groups. In this sense, 
of the 42 subjects with QEIR, 23 (54.8%) presented at 
least one opportunistic oral infection associated to HIV 
disease. The OOI-HIV diagnosed in this group were the 
following: erythematous candidiasis in 12 cases; HL in 
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ERA OOI-HIV EC PC HC AC LH HL KS 
PRE-
HAART 
57  
(66.3%) 
27 
(31.4%) 
11 
(12.8% 
6 
(7%) 
20 
(23.3%) 
7 
(8.1%) 
18 
(20.9%) 
4 
(4.7%) 
HAART 
40 
(46.5%) 
25 
(29.1%) 
4 
(4.7%) 0 
8 
(9.4%) 
1 
(1.2%) 
20 
(23.3%) 0 
 HAART = HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; PRE-HAART = 1996; HAART ERA = ≥1997; OOI-HIV = 
OPPORTUNISTIC ORAL INFECTIONS RELATED TO HIV INFECTION; EC = ERYTHEMATOUS CANDIDIASIS; PC 
= PSEUDOMEMBRANOUS CANDIDIASIS; HC = HYPERPLASTIC CANDIDIASIS; AC = ANGULAR CHEILITIS; 
LH = LIP HERPES; HL = HAIRY LEUKOPLAKIA; KS = KAPOSI SARCOMA.
Table 2. Prevalences of opportunistic oral infections among the 86 HIV+/AIDS patients analyzed in the different treatment 
eras.
HAART = HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; PRE-HAART = 1996; HAART ERA = ≥1997; QEIR = QUAN-
TITATIVE EVIDENCE OF IMMUNE RECONSTITUTION; QEIR+VL = QUANTITATIVE EVIDENCE OF IMMUNE 
RECONSTITUTION PLUS UNDETECTABLE VIRAL LOADS; QEIRm+VL = MAXIMUM QUANTITATIVE EVIDENCE 
OF IMMUNE RECONSTITUTION PLUS UNDETECTABLE VIRAL LOADS (CD4+ COUNTS OF >500/ml)
Table 1. Demographic data of the 86 HIV+/AIDS patients studied.
STUDY GROUP N
TOTAL 86
GENDER fEmALE 44mALE 42
fORm Of CONTAGION
HETEROSEXUAL 19
 mALE HOmOSEXUAL 34
INTRAVENOUS DRUG ABUSE 33
ImmUNE STATUS
PRE-HAART 
ERA
mILD ImmUNE SUPPRESSION 22
mODERATE ImmUNE 
SUPPRESSION 22
SEVERE ImmUNE 
SUPPRESSION 42
HAART ERA
mILD ImmUNE SUPPRESSION 30
mODERATE ImmUNE 
SUPPRESSION 28
SEVERE ImmUNE 
SUPPRESSION 28
VIROLOGICAL 
STATUS HAART ERA
UNDETECTABLE VIRAL LOAD 39
<10,000 COPIES 25
>10,000 COPIES 22
RESPONSE TO 
HAART
QEIR 42
QEIR+VL 21
QEIRm+VL 17
TImE UNDER 
HAART (in years)
1 24
2 15
4 28
9 19
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GROUP OOI-HIV EC PC AC LH HL 
QEIR 
(42) 
23 
(54.8%) 
12 
(28.6%) 
1 
(2.4%) 
4 
(9.5%) 
1 
(2.4%) 
10 
(23.8%) 
QEIR+VL 
(21) 
7 
(33.8%) 
5 
(23.8%) 
1 
(4.8%) 
2 
(9.5%) 0 
4 
(19%) 
QEIRm+VL 
(17) 
6 
(35.3%) 
4 
(23.5%) 
4 
(23.5%) 
2 
(11.8%) 0 
4 
(23.5%) 
 QEIR = QUANTITATIVE EVIDENCE OF IMMUNE RECONSTITUTION; QEIR+VL = QUANTI-
TATIVE EVIDENCE OF IMMUNE RECONSTITUTION PLUS UNDETECTABLE VIRAL LOADS; 
QEIRm+VL = MAXIMUM QUANTITATIVE EVIDENCE OF IMMUNE RECONSTITUTION PLUS 
UNDETECTABLE VIRAL LOADS (CD4+ COUNTS OF >500/ml); HAART = HIGHLY ACTIVE 
ANTIRETROVIRAL THERAPY; OOI-HIV = OPPORTUNISTIC ORAL INFECTIONS RELATED TO 
HIV INFECTION; EC = ERYTHEMATOUS CANDIDIASIS; PC = PSEUDOMEMBRANOUS CAN-
DIDIASIS; AC = ANGULAR CHEILITIS; LH = LIP HERPES; HL = HAIRY LEUKOPLAKIA. 
Table 3. Prevalence of opportunistic oral infections in relation to the different study groups. 
Table 4. Prevalence of oral lesions in relation to the duration of highly active antiretroviral therapy in each of the study 
groups. 
OOI-HIV = OPPORTUNISTIC ORAL INFECTIONS RELATED TO HIV INFECTION; HAART = HIGHLY 
ACTIVE ANTIRETROVIRAL THERAPY
YEARS UNDER HAART
STUDY GROUP 1 2 4 9
ImmUNE 
RESPONSE
OOI-HIV 3/11(27.3%)
2/5
(40%)
6/12
(50%
8/14
(57.1%)
mYCOTIC 3/5(60%)
6/12
(50%)
8/14
(57.1%)
VIRAL 3/11(27.3%)
2/5
(40%)
3/12
(25%)
3/14
(21.4%)
EVIDENCE 
Of ImmUNE 
RECONSTITUTION
OOI-HIV 1/5(20%)
1/4
(25%)
2/4
(50%)
3/8
(37.5%)
mYCOTIC 2/4(50%)
3/4
(75%)
3/8
(37.5%)
VIRAL 1/5(20%)
1/4
(25%)
1/4
(25%)
1/8
(12.5%)
TOTAL SUCCESS
OOI-HIV 1/4(25%)
1/4
(25%)
2/4
(50%)
2/5
(60%)
mYCOTIC 2/4(50%
3/4
(75%)
2/5
(40%)
VIRAL 1/4(25%)
1/4
(25%
1/4
(25%)
1/5
(20%)
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10 cases, and angular cheilitis in 4 cases. One case of lip 
herpes and one case of pseudomembranous candidiasis 
were also diagnosed. 
In the case of the patients with QEIR+VL, and of the 
21 individuals that met the selection criteria, 7 presented 
at least one OOI-HIV. In this group we identified 4 cases 
of HL, 5 cases of erythematous candidiasis, two cases of 
angular cheilitis, and one case of  pseudomembranous 
candidiasis.
Of the 17 subjects with QEIRm+VL (CD4+ lymphocyte 
count >500/ml and undetectable viral load), 6 presented 
some type of OOI-HIV. Specifically, we diagnosed 4 cases 
of HL, 4 cases of erythematous candidiasis, two cases 
of angular cheilitis and one case of pseudomembranous 
candidiasis. The total opportunistic infections diagnosed 
in each group are shown in Table 3. 
In relation to the duration of HAART, and as can be seen 
in Table 4, the subjects with QEIR showed an increased 
prevalence of OOI-HIV with the prolongation of HAART 
(p = 0.008). However, when analyzed according to the 
underlying etiology, we found that the lesions of  viral 
origin, HL and herpes simplex, showed no association to 
the time elapsed. In contrast, the lesions of mycotic origin 
appeared later in time, after 24 months of HAART. 
On examining the QEIR+VL population, the oral lesions 
of viral origin were seen to remain constant, while the 
total lesions and infections of mycotic origin showed no 
apparent trends. In the case of the patients with maximum 
immune reconstitution (QEIRm+VL), we likewise recor-
ded an increase in the prevalence of OOI-HIV over time, 
together with the constant presence of viral lesions. 
Discussion
The present study reflects the possibility that opportunistic 
oral infections associated to HIV infection may manifest 
as a consequence of  immune reconstitution in certain 
HIV+/AIDS patients subjected to HAART. An important 
finding in our series is that HIV+/AIDS patients subjected 
to HAART who present CD4+ lymphocyte counts of 
>500/ml and undetectable viral loads can suffer OOI-HIV. 
Practically all studies on oral morbidity in HIV+/AIDS 
patients receiving HAART, and in which the prevalence of 
oral lesions is associated to immune and virological status, 
report that some patients with CD4+ lymphocyte counts 
of >500/ml and undetectable viral loads have oral lesions 
(11-17). In other words, none of the published series of 
HIV+/AIDS patients subjected to HAART have been 
able to demonstrate the absence of oral lesions among the 
global patients receiving successful antiretroviral therapy. 
An important observation is the fact that despite reaching 
quantitatively optimum CD4+ lymphocyte counts and 
viremia control to undetectable levels, clinically manifest 
oral lesions can appear. The hypothesis that some of these 
lesions in such patients may be the result of a reconstitutive 
immune response is attractive.
The chain of  events leading to immune reconstitution 
inflammatory syndrome (IRIS) is not clear. A short-term 
effect of antiretroviral treatment is that it preserves pre-
therapy immune system competence - thereby slowing 
disease progression and improving patient survival. On 
the other hand, if  antiretroviral therapy controls vire-
mia, T-cell clone expansion may occur, thereby allowing 
improved immune function (18). The reason why not all 
patients with immune reconstitution develop IRIS, and the 
characteristics and parameters that differentiate the two 
population groups, have not been established.
The pathogenesis of IRIS is multifactorial, and depends 
on the amount of  pre-existing microorganisms, their 
virulence, and the characteristics of particular immune 
response (5,6). During the first four weeks after the start 
of HAART, an increase is seen in the circulating CD4+ 
cells, more associated with a redistribution of memory 
cell entrapped within the lymphoid tissue than with a new 
production of naïve cells (7). In the months following the 
start of HAART, viremia is brought under control, and 
this leads to restoration of thymus gland function - with 
a second increase in circulating CD4+ lymphocytes, this 
time related to the production of naïve CD4+ cells (7).
Approximately 20-30% of  all patients subjected to 
HAART develop IRIS (7). Our results generally coin-
cide with the data published in the literature, since the 
sample of patients with quantitative evidence of immune 
competence and controlled viremia showed a prevalence 
of OOI-HIV of 33.8% (versus 35% on reaching maxi-
mum immune competence). Different clinical conditions 
have been associated with IRIS, including herpes zoster, 
Kaposi sarcoma, Graves’ disease, progressive multifocal 
leukoencephalopathy, as well as infections due to cytome-
galovirus, Pneumocystis carinii, hepatitis B and C viruses, 
Mycobacterium avium complex, Mycobacterium tuber-
culosis, or Cryptococcus neoformans (19,20). However, 
few studies have addressed the oral lesions associated 
with IRIS. The facial lesions reported as part of IRIS 
are fundamentally attributable to herpes zoster (7), and 
molluscum contagiosum (21). Intraorally, there have been 
three reports of Kaposi sarcoma associated to IRIS (22). 
All three are OOI-HIV of viral origin. None of  these 
lesions were identified in our series of patients. The fact 
that only viral oral lesions have associated with IRIS may 
be due to the fact that none of these studies conducted 
long-term follow-up. In this context, our results suggest 
that opportunistic mycotic infections re-emerge after more 
than 12 months. The most frequent OOI-HIV was found 
to be oral candidiasis (OC). Of note is the fact that there 
are no studies on the presence of OC associated to IRIS. 
Our results indicated a prevalence of OC of close to 30%, 
including one case of pseudomembranous candidiasis. In 
contrast, other clinical studies report that the initial syste-
mic opportunistic infections in IRIS are caused by fungal 
species (Cryptococcus spp.) or mycobacteria (Mycobac-
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terium tuberculosis, Mycobacterium avium complex)(7), 
and that viral infections appear at a later point in time. The 
time-analysis of our cases indicates that mycotic lesions 
are identified in later stages.
In the present series, the lesions most commonly identified 
in the population with immune reconstitution were HL 
and OC. Erythematous candidiasis showed very constant 
values in the four study groups, with a slight improvement 
in the patients with QEIR+VL. The prevalence of OC 
(excluding angular cheilitis) in our subjects with QEIR was 
found to be 30%, i.e., clearly greater than the 9% preva-
lence reported by Umadevi et al. (16) in subjects receiving 
HAART and with CD4+ lymphocyte counts of over 200/
ml (16). If  our finding is confirmed, and considering that 
both types of lesions - particularly OC (10,23) - have been 
reported to be of great prognostic value (their presence 
moreover being considered suggestive of  antiretroviral 
therapy failure)(10,24), then it would become necessary 
to establish the differential diagnostic parameters between 
lesions associated to IRIS and oral lesions associated to 
immune deficiency. To date, no parameters for the diffe-
rential diagnosis of lesions due to persistence, reinfection 
or a vigorous host immune response have been identified. 
Such is the case of pseudomembranous candidiasis. The 
presence of this clinical variety of candidiasis has been 
proposed as an immune suppression marker (25). Howe-
ver, in our series we recorded a case of pseudomembranous 
candidiasis in a QEIRm+VL patient. This finding raises 
new questions, and the importance of differentiating the 
origin of such lesions (secondary to immune competence 
or to immune deficiency), with a view to management and 
antiretroviral treatment decisions, is obvious. In fact, it is 
always recommended to distinguish between clinical fa-
ilure of antiretroviral therapy and immune reconstitution 
inflammatory syndrome. At present, it has been proposed 
that the diagnosis of lesions associated to IRIS should be 
made on an exclusion basis (7). There are no differences in 
paraclinical marker values associated to IRIS. Our results 
agree with this suggestion, since the study groups showed 
no statistical association between the CD4+ lymphocyte 
counts or viral loads and oral lesions. The lack of scien-
tific information regarding the behavior of OOI-HIV in 
subjects with immune reconstitution prevents us from 
specifying whether this condition is pertinent in the case 
of oral lesions.
In the present study, the viral lesions diagnosed in subjects 
with immune reconstitution corresponded to the family 
Herpes viridae. A case of lip herpes and 10 cases of HL 
were identified. Of note is the behavior of HL in our se-
ries. The constant presence of hairy leukoplakia in all the 
groups, regardless of the response (success or failure) to 
antiretroviral therapy (HAART) or the duration of such 
treatment, suggests that HL does not form part of the 
clinical picture of IRIS. In effect, HL remained practically 
constant in all the study groups, regardless of the time 
under HAART. This can be explained by the demons-
tration of both a high prevalence of Epstein-Barr virus 
carriers and of high viral loads corresponding to this same 
virus in HIV+ subjects under to HAART (26). The fact 
that cases of HL were recorded in subjects with immune 
reconstitution and with undetectable viral loads again 
reflects the importance of incorporating this possibility in 
the prognostic role of these viral lesions. Although HL has 
been associated to CD4+ lymphocyte counts of <200/ml 
(25), it also has been suggested that susceptibility to HL 
is not necessarily associated to impaired mucosal immune 
function (27). Our results support this latter possibility.
A point that should be stressed is that among the four 
study groups, the group with the highest prevalence of 
OOI-HIV corresponded to the patients with maximum 
immune competence and undetectable viral loads (56.3%), 
while the group with the lowest prevalence was that con-
sidering only an increase in CD4+ lymphocyte counts 
under HAART. On adjusting the sample in relation to 
undetectable viral load, the prevalence of  such lesions 
increased. This suggests that a risk factor additional to an 
increase in the number of CD4+ lymphocytes is viremia 
control. This suggestion has been published elsewhere. It 
has been reported that lesions of infectious origin asso-
ciated to IRIS are mainly found in subjects who before 
the introduction of  HAART suffered severe immune 
depression and/or viral loads of >10,000 copies/ml, and 
who under HAART reached CD4+ lymphocyte counts of 
>500/ml (28). Our results indicate that the subjects with 
greatest immune reconstitution (i.e., the QEIRm+VL 
group) exhibit a slightly greater presence of oral lesions 
than the patients who fail to reach such levels of immune 
competence.
It has been proposed that the lesions associated to IRIS 
manifest between 4-8 weeks after the start of HAART. 
However, there have been reports of cases manifesting 
even 80 weeks after the start of HAART (7). In our pa-
tients with immune reconstitution, the fewest diagnoses 
of OOI-HIV corresponded to subjects with one year or 
less of HAART. In this context, a gradual and statistically 
significant increase in lesions was seen over time under 
HAART. This suggests that successful HAART secures 
immediate control of OOI-HIV, as evidenced by the very 
low prevalence of  such lesions recorded in the period 
immediately after the introduction of  protease inhibi-
tors to antiretroviral therapy, and that as the time under 
HAART increases, another immune competent factor is 
needed (in addition to the quantitative boost in immune 
function) in order to ensure an optimum oral mucosal 
immune response. This hypothetical factor presumably 
would require more time for reconstitution than the CD4+ 
lymphocyte count. It has been suggested that viewing HIV 
infection simply as a decrease in CD4+ lymphocyte count 
is too simplistic, in view of the extreme complexity of the 
host immune response (18). Another possible explanation 
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for the above finding could be that the Candida strains 
that colonize the oral mucosa in HIV+ patients receiving 
HAART acquire resistance to the HIV-1 protease inhibi-
tors, which have been considered to possess anti-Candida 
effects (29). However, it is also possible that these cases of 
OC may be due to qualitative exhaustion of the immune 
system. On the other hand, if  time is the most important 
factor for differentiating IRIS from a delay in acquiring a 
competent immune capacity, then it could be speculated 
that our results - particularly those relating to 24 months 
of HAART - could be associated to IRIS, while posterior 
lesions could be the result of a delay in immune improve-
ment or of immune function exhaustion or failure. The 
clarification of these aspects falls outside the scope of the 
present study, and specific investigational protocols should 
be defined to explore them. Furthermore, it recently has 
been demonstrated that oral lesion morbidity associated 
to HIV disease is present in the HIV+ population under 
to HAART in the present era (30,31).
The confirmation of whether OOI-HIV can form part 
of the clinical picture of IRIS is necessary. At present we 
are unable to rule out the possibility that these lesions 
are the consequence of a qualitative failure of immune 
cell response; of the incomplete acquisition of mucosal 
immune response following HAART; or simply examples 
of de novo infection.
The present study shows the human immunodeficiency 
syndrome to be a dynamic disorder characterized by an 
intense inter-relationship with therapy (and the conse-
quences this has for the patient); as a result, it is very 
difficult to establish a prognosis once treatment has been 
started.
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